This MicroRNA Might Help Detect, Treat Ovarian Cancer

June 26, 2020 6:00 pm

In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

By Ian Demsky

A microRNA that is normally involved in immune cell differentiation helps to initiate

Read more

KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers

May 11, 2020 10:30 am

By Ian Ingram

For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.

Among women treated with … Read more

FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer

May 11, 2020 10:00 am

NEW YORK – The US Food and Drug Administration has approved olaparib (AstraZeneca/Merck’s Lynparza) in combination with bevacizumab (Genentech’s Avastin) as a maintenance regimen for advanced ovarian cancer patients who have homologous recombination deficiency (HRD) and are responding to first-line … Read more

Blood Test Helped Detect Cancer Before Symptoms, Study Finds

April 28, 2020 10:45 am

by Marilynn Marchione

For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of the disease.

The test is still experimental. … Read more

AACR 2020: Cell-Free DNA Liquid Biopsy May Provide an Early Detection Test for Patients With Suspected Cancer

April 28, 2020 10:30 am

By Jo Cavallo

The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early … Read more

Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the AACR 2020 Virtual Annual Meeting I

April 27, 2020 10:20 am

BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its

Read more

First-in-Human Study of RAF Family Kinase Inhibitor Lifirafenib in Solid Tumors

March 27, 2020 12:30 pm

By Matthew Stenger

In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or … Read more

New Research Shows Which Ovarian Cancer Patients Won’t Benefit From Immune-PARP Combo

March 19, 2020 10:10 am

BOSTON – In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven’t been able to predict which patients … Read more

Simple Blood Test Measures the Body’s Immune Response to Improve Ovarian Cancer Diagnosis

February 17, 2020 10:00 am

Researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis of ovarian cancer.

Ovarian cancer is one of the most common gynecologic cancers, with the highest mortality rate. About 300,000 new cases are … Read more

Novel Ovarian Cancer Diagnostic May Eliminate Need for Exploratory Surgery

June 21, 2019 6:00 pm

Scientists at Uppsala University and the Sahlgrenska Academy, University of Gothenburg say they have developed a blood test that may provide a more precise diagnostic for suspected ovarian cancer that would eliminate the need for exploratory surgery. This could lead … Read more

Research Could Lead to More Precise Diagnosis and Treatment of Ovarian Cancer

May 8, 2019 5:00 pm

By Michael Brown

Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a national research study co-led out of the University of … Read more

Cancer DNA Binds to Gold. That Could Lead to New Cancer Blood Test.

December 5, 2018 7:30 pm

By Rachael Rettner, Senior Writer

Researchers have discovered a curious difference between the DNA from cancer cells and that from healthy cells, and this finding could lead to a new blood test for cancer.

The difference? Cancer DNA has a … Read more

Early Clinical Trials Showing Promise for New Kind of Cancer Vaccine

September 30, 2018 3:14 pm

By Rich Haridy

Promising early results are in from a phase 1 clinical trial into the safety and efficacy of a new cancer vaccine. The new treatment is designed to stimulate the immune system into attacking certain cancers known to … Read more

Novel Biomarker Found in Ovarian Cancer Patients Can Predict Response to Therapy

September 27, 2018 6:58 pm

Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but never to a cure. About 15 percent of

Read more

Squelching Ovarian Cancer: The Not-So-Silent Killer

September 17, 2018 12:08 am

By Diane Mapes

Despite its long-standing nickname, ovarian cancer isn’t really a silent killer. There are symptoms; it’s just that they whisper or are commonly mistaken for something else, like aging or irritable bowel syndrome. As a result of this

Read more

FDA Approves Cancer Drug for a Biomarker Not a Tissue

May 31, 2017 8:26 pm

Colon, pancreatic, stomach, or ovarian cancer; it increasingly shouldn’t matter. In an era of precision medicine, the treatment approach should reflect the genetic makeup of the person’s tumor and the presence or absence of key biomarkers.

That ethos was set … Read more

In Ovarian Cancer Advancements, Finding New Biomarkers Is Key

January 5, 2017 9:02 pm

The search for validated, actionable biomarkers may be more important than initiating more phase 3 trials in the field of ovarian cancer, according to Maurie Markman, M.D.

“In the ovarian cancer arena, we have 30 years of history of doing … Read more